Ultragenyx Pharmaceutical, Inc. (RARE)
16.07
-0.20
(-1.23%)
USD |
NASDAQ |
Nov 13, 16:00
16.07
0.00 (0.00%)
After-Hours: 19:59
Ultragenyx Pharmaceutical Net Income (Quarterly) : -118.00M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -118.00M |
| June 30, 2026 | -92.00M |
| March 31, 2026 | -185.00M |
| December 31, 2025 | -129.00M |
| September 30, 2025 | -180.41M |
| June 30, 2025 | -114.95M |
| March 31, 2025 | -151.08M |
| December 31, 2024 | -133.38M |
| September 30, 2024 | -133.52M |
| June 30, 2024 | -131.60M |
| March 31, 2024 | -170.68M |
| December 31, 2023 | -123.19M |
| September 30, 2023 | -159.65M |
| June 30, 2023 | -159.83M |
| March 31, 2023 | -163.97M |
| December 31, 2022 | -151.83M |
| September 30, 2022 | -245.11M |
| June 30, 2022 | -158.16M |
| March 31, 2022 | -152.32M |
| December 31, 2021 | -122.46M |
| September 30, 2021 | -73.00M |
| June 30, 2021 | -122.43M |
| March 31, 2021 | -136.14M |
| December 31, 2020 | -24.01M |
| September 30, 2020 | -68.84M |
| Date | Value |
|---|---|
| June 30, 2020 | 25.32M |
| March 31, 2020 | -119.02M |
| December 31, 2019 | -93.80M |
| September 30, 2019 | -112.99M |
| June 30, 2019 | -99.17M |
| March 31, 2019 | -96.76M |
| December 31, 2018 | -87.83M |
| September 30, 2018 | -87.31M |
| June 30, 2018 | -52.73M |
| March 31, 2018 | 30.25M |
| December 31, 2017 | -81.73M |
| September 30, 2017 | -79.23M |
| June 30, 2017 | -72.89M |
| March 31, 2017 | -68.29M |
| December 31, 2016 | -71.29M |
| September 30, 2016 | -64.91M |
| June 30, 2016 | -56.92M |
| March 31, 2016 | -52.76M |
| December 31, 2015 | -55.22M |
| September 30, 2015 | -39.23M |
| June 30, 2015 | -29.79M |
| March 31, 2015 | -21.38M |
| December 31, 2014 | -16.74M |
| September 30, 2014 | -15.85M |
| June 30, 2014 | -13.58M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | -109.97M |
| AbbVie, Inc. | 4.207B |
| Krystal Biotech, Inc. | 63.07M |
| BridgeBio Pharma, Inc. | -60.50M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 173.00M |
| Total Expenses (Quarterly) | 291.00M |
| EPS Diluted (Quarterly) | -1.156 |
| Enterprise Value | 2.577B |
| Gross Profit Margin (Quarterly) | 76.30% |
| Profit Margin (Quarterly) | -68.21% |
| Earnings Yield | -32.29% |
| Normalized Earnings Yield | -32.29 |